Elranatamab Represents Another Off-the-Shelf Option for Heavily Pretreated R/R Myeloma

Ajay Kumar Nooka, MD, MPH, FACP, highlights the significance of the FDA approval of elranatamab for select patients with relapsed/refractory multiple myeloma and expands the agent’s role in the expanding field of T cell–redirecting therapies approved for the treatment this patient population.

Related Keywords

Emory University ,Georgia ,United States ,Atlanta ,Ajay Kumar Nooka ,Oncology At Emory University School Of Medicine ,Department Of Hematology ,Myeloma Program ,Pfizer ,Medical Oncology ,Emory University School ,Winship Data ,Technology Applications Shared Resource ,Winship Cancer Institute ,Elranatamab ,Multiple Myeloma ,Myeloma ,Bcma Directed Therapy ,Bcma ,Antibody Drug Conjugate ,Sadc ,Cart Cell Therapy ,Car T ,Pf 06863135 ,Magnetismm 1 ,Magnetismm 2 ,Magnetismm 3 ,Magnetismm 9 ,Ajayk Nooka ,Bbs ,